USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
RATIONAL BIOTECHNOLOGY, INC.
Address:
RATIONAL BIOTECHNOLOGY, INC.
115 Constitution Dr, STE 7
Menlo Park, CA 94025
Phone:
N/A
URL:
N/A
EIN:
810666869
DUNS:
615333593
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $548,417.00 2
SBIR Phase II $1,306,728.00 1

Award List:

Surefection Technology for High-Throughput Primary Cell Transfection

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$199,670.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Human primary cells are cells directly derived from tissue samples from patients or healthy donors. They are the truest in vitro models of human physiology and disease, therefore are invaluable in medical discovery and development. Use of human primary cells as… More

SureFection Technology for High-Throughput Primary Cell Transfection

Award Year / Program / Phase:
2008 / SBIR / Phase II
Award Amount:
$1,306,728.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Use of human primary cells (from health donors or patients) as physiology- or disease-relevant models provides significant advantages in basic research and therapeutic development for understanding and treating various human diseases, including cancer,… More

Targeted siRNA Delivery to Liver with EIT guided Sonoporation

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$348,747.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): RNA interference (RNAi), a biological process for modulating gene expression using short interfering RNA (siRNA) molecules, has emerged as one of the most promising technologies for treating a wide range of difficult-to -cure diseases, including liver diseases,… More